Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ) has been invited to present the latest results from its novel blood test for oesophageal adenocarcinoma at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada, 8-10 September 2023.
In this interview, Dr. Richard Lipscombe, Managing Director of Proteomics International Laboratories Limited (ASX:PIQ), talks about the agreement recently entered into with Sonic Healthcare (USA).
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has signed an exclusive licence agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it will present its potential new blood test for endometriosis at the world's leading endometriosis conference.
Proteomics International Laboratories Ltd (ASX:PIQ) in collaboration with Janssen Research & Development have shown that treatment with Canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce results showing a significant reduction in the PromarkerD risk scores of patients with type 2 diabetes after taking the diabetes medicine canagliflozin.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide the following update on its business activities for the three months to 31 March 2023 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has appointed additional members to its Clinical Advisory Board adding world leading healthcare professionals from the United States.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the National Association of Testing Authorities (NATA) of Australia has approved the continuation of the Company's ISO 17025 accreditation.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its potential new world-first blood test for diagnosing endometriosis.
Issue of Equity Incentives to Employees
Interim Financial Report and Appendix 4D
Issue of Equity Incentives to Employees
Notice of Annual General Meeting/Proxy Form
